Patent details
301029
Product Name:
Eftrenonacog alfa of een biosimilair product op grond van Artikel 10(4) van Richtlijn 2001/83/EG.
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301029
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP3225233
Status:
Refused Art. 10 of the EC Regulations
Application number:
301029
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)
Marketing Authorization
Marketing Authorization Number:
EU/1/16/1098
Marketing Authorization Type:
EEA
Marketing Authorization Date:
13/05/2016
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
23/01/2020
First Marketing Authorization date:
13/05/2016
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
28/01/2020
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
03/07/2024
Applicant/holder
From:
23/01/2020
Name:
Wyeth LLC
Address:
235 East 42nd Street, NY 10017, New York , United States of America (US)
Agent
Name:
ir. M.F.J.M. Ketelaars c.s.
From:
23/01/2020
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
28/24
Publication date:
10/07/2024
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
05/20
Publication date:
29/01/2020
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
03/07/2024
Outgoing Correspondence
Decision refusal
2
PDF
/2/0/2/0/1/0800510202/docs/301029_11_610566l527a.pdf
25/04/2024
Outgoing Correspondence
Letter to applicant
1
PDF
/2/0/2/0/1/0800510202/docs/301029_10_601936l173.pdf
03/02/2020
Front Page
Front Page
1
PDF
/2/0/2/0/1/0800510202/docs/301029_0_i1frontpage20200203140650661.pdf
03/02/2020
Publication
Publication
1
PDF
/2/0/2/0/1/0800510202/docs/301029_1_i1document20200203140651156.pdf
03/02/2020
Outgoing Correspondence
Confirmation receipt request
1
PDF
/2/0/2/0/1/0800510202/docs/301029_5_322747l174.pdf
23/01/2020
SPC Documents
Annex SPC
2
PDF
/2/0/2/0/1/0800510202/docs/301029_2_supplprotectioncertificate20200128043358949.pdf
23/01/2020
SPC Documents
Annex SPC
11
PDF
/2/0/2/0/1/0800510202/docs/301029_3_supplprotectioncertificate20200128043358790.pdf
23/01/2020
SPC Documents
Annex SPC
19
PDF
/2/0/2/0/1/0800510202/docs/301029_4_supplprotectioncertificate20200128043359033.pdf
23/01/2020
SPC Documents
Summary of the characteristics of the product
13
PDF
/2/0/2/0/1/0800510202/docs/301029_6_supplprotectioncertificate20200128043358866.pdf
23/01/2020
Incoming Correspondence Paper
Accompanying letter incoming document
1
PDF
/2/0/2/0/1/0800510202/docs/301029_7_incomingcorrespondencepaper20200203014654538.pdf
23/01/2020
Application Form
First filed application form
2
PDF
/2/0/2/0/1/0800510202/docs/301029_8_applicationform20200128043358438.pdf
23/01/2020
SPC Documents
Marketing Authorization SPC
4
PDF
/2/0/2/0/1/0800510202/docs/301029_9_supplprotectioncertificate20200128043358695.pdf